Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).

Study Overview

• Status: Completed
• Conditions: Healthy; Renal Insufficiency
• Intervention / Treatment: Biological: MGTA-145

Detailed Description

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Orlando, Florida, United States, 32809
      • Orlando Clinical Research Center (OCRC)
  • Tennessee
    • Knoxville, Tennessee, United States, 37920
      • Alliance for Multispeciality Research (AMR) Formerly New Orleans Center for Clinical Research (NOCCR)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion criteria for all subjects:

1. Age from 18 to 79 years, inclusive, at the time of signing of the ICF.
2. Body weight ≥50 kg and BMI 19 to 40 kg/m2, inclusive.
3. Systolic blood pressure ≤170 mmHg and diastolic blood pressure ≤100 mmHg at Screening and Day 1.
4. No clinically significant abnormalities on physical examination at Screening.
5. Alanine aminotransferase and aspartate aminotransferase up to 1.5 x the upper limit of normal (ULN) as long as total bilirubin and alkaline phosphatase are ≤ ULN.
6. No clinically significant abnormalities on ECG and QTcF <480 msec at Screening.
7. Female subjects are not pregnant, non-lactating, and must be of non-childbearing potential being either surgically sterile (eg, documented hysterectomy, bilateral oophorectomy, bilateral salpingo oopherectomy, tubal ligation) or post-menopausal women (over 45 years of age with 12 months or more amenorrhea verified by follicle stimulating hormone assessment and the absence of other biological or physiological causes).
8. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or those who are sexually active with a female partner(s) and agree to use an acceptable method of contraception (such as condom with spermicide) combined with an acceptable method of contraception for their non-pregnant female partner(s) after informed consent, throughout the study, and for a minimum of 90 days after the last dose, and who do not intend to donate sperm in the period from Screening until 3 months following administration of the study drug.
9. Subject using medications known to affect the elimination of serum creatinine (eg, cimetidine, trimethoprim) within the past 30 days.

10. Capable of providing informed consent and willing to comply with the requirements of the protocol.

    Specific inclusion criteria for subjects with NORMAL renal function:

11. Estimated GFR (based on MDRD equation) ≥90 mL/min/1.73 m2 (normal) as determined by an average of 2 values obtained at least 48 hours apart within the previous 3 months.

12. White blood cell (WBC) count, hemoglobin and platelet count within normal limits. Absolute neutrophil count of >1500/µL for African Americans and >2000/µL for other races.

    Specific inclusion criteria for subjects with RENAL IMPAIRMENT:

13. Estimated GFR <90 mL/min/1.73 m2 (based on MDRD equation) as determined by an average of 2 values obtained at least 48 hours apart and within the previous 3 months.
14. Stable renal function as determined by <20% difference in serum creatinine obtained on 2 occasions at least 48 hours apart and within the previous 3 months.
15. Platelet count ≥100,000/mm3, hemoglobin count ≥10g/dL, WBC count within normal limits. Absolute neutrophil count of >1500/µL for African Americans and >2000/µL for other races.

Exclusion criteria for all subjects:

1. Clinically significant abnormal finding on physical examination conducted at Screening. The assessment may be repeated once prior to treatment number assignment. If the repeat value(s) remains outside of protocol-specified ranges, the subject will be excluded from the study. Note: Re assessment is not allowed for subjects who have a positive urine drug screen test at Screening.
2. History of chronic alcohol or drug abuse within the previous 12 months. Subject has a positive pre-study drug/alcohol screen (to include at minimum: amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepines, and myelosuppressive drugs). A subject with a positive finding on the drug screen may still be enrolled at the discretion of the Investigator if a plausible clinical explanation exists (eg, prior or concomitant medication use).
3. History of kidney transplantation or requiring dialysis or anticipated to initiate dialysis during the study period.
4. Donation of more than 500 mL of blood or plasma within 12 weeks prior to dosing.
5. Subject smokes more than 10 cigarettes per day (or equivalent) or has done so within 6 months prior to the Screening Visit.
6. Acute illness, infection (requiring medical treatment [eg, antibiotics]), or surgery within 30 days of dosing.
7. Seropositive for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus.
8. Subject has received another investigational drug or participated in an investigational device study within 30 days prior to dosing.

9. History of anaphylaxis or clinically important reaction to any drug including plerixafor.

   Specific exclusion criteria for subjects with NORMAL renal function:

10. Any clinically significant laboratory value outside the normal range at Screening. The assessment may be repeated once prior to treatment number assignment. If the repeat value(s) remains outside of protocol-specified ranges, the subject will be excluded from the study. Note: Re assessment is not allowed for subjects who have a positive urine drug screen test at Screening.
11. Any clinically significant hematologic, cardiovascular, pulmonary, central nervous system, metabolic, hepatic, or gastrointestinal conditions or history of conditions that, in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this study or may interfere with the interpretation of the study results.

12. Subject has used any prescription drugs within 14 days prior to dosing or any dietary supplements or non prescription drugs within 7 days prior to dosing unless deemed acceptable by the Investigator and Sponsor (Magenta Medical Monitor).

    Specific exclusion criteria for subjects with RENAL IMPAIRMENT:

13. Presence of acute kidney injury.
14. Clinically significant laboratory abnormalities excluding those associated with renal impairment or the underlying cause of renal disease.
15. Unstable medical condition or underlying medical condition that has changed within the past 90 days.
16. Presence of laboratory abnormalities or clinically significant medical condition that in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this study or may interfere with the interpretation of the study results.
17. Changes in prescription medications within 14 days prior to dosing or anticipated changes during the study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Normal kidney function; MGTA-145 single dose	Biological: MGTA-145; MGTA-145 will be given intravenously
Experimental: Mild decrease in GFR; MGTA-145 single dose	Biological: MGTA-145; MGTA-145 will be given intravenously
Experimental: Moderate decrease in GFR; MGTA-145 single dose	Biological: MGTA-145; MGTA-145 will be given intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics Biomarkers	Investigate area under the curve (AUC)	2 days
Pharmacokinetics Biomarkers	Investigate maximum plasma concentration (Cmax)	2 days
Pharmacokinetics Biomarkers	Investigate clearance (CL)	2 days
Pharmacokinetics Biomarkers	volume of distribution at steady state (Vdss)	2 days
Pharmacokinetics Biomarkers	Investigate half-life	2 days
Pharmacokinetics Biomarkers	Investigate renal clearance of MGTA-145	2 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability	Investigate the safety and tolerability of MGTA-145 following intravenous (IV) administration as monotherapy in subjects with varying degrees of renal impairment (e.g. adverse events, clinical laboratory tests, vital signs, ECGs)	15 days

Collaborators and Investigators

• Sponsor: Ensoma
• Investigators: Study Director: Will Savage, MD, PhD, Magenta Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): November 7, 2019
• Primary Completion (Actual): March 24, 2020
• Study Completion (Actual): March 24, 2020

Study Registration Dates

• First Submitted: November 4, 2019
• First Submitted That Met QC Criteria: November 5, 2019
• First Posted (Actual): November 6, 2019

Study Record Updates

• Last Update Posted (Actual): January 11, 2024
• Last Update Submitted That Met QC Criteria: January 9, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Renal Insufficiency
• Other Study ID Numbers: 145-RI-102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No